Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - authors' reply
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) Editorial |
| Sprache: | Englisch |
| Veröffentlicht: |
1 December 2017
|
| In: |
The lancet. Oncology
Year: 2017, Jahrgang: 18, Heft: 12, Pages: e709-e710 |
| ISSN: | 1474-5488 |
| DOI: | 10.1016/S1470-2045(17)30856-2 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/S1470-2045(17)30856-2 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1470204517308562 
|
| Verfasserangaben: | Michael Weller, Nicholas Butowski, David D Tran, Lawrence D Recht, Michael Lim, Hal Hirte, Lynn Ashby, Laszlo Mechtler, Samuel A Goldlust, Fabio Iwamoto, Jan Drappatz, Donald M O'Rourke, Mark Wong, Mark G Hamilton, Gaetano Finocchiaro, James Perry, Wolfgang Wick, Jennifer Green, Yi He, Christopher D Turner, Michael J Yellin, Tibor Keler, Thomas A Davis, Roger Stupp, John H Sampson |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1584414928 | ||
| 003 | DE-627 | ||
| 005 | 20220815064019.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181126s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1470-2045(17)30856-2 |2 doi | |
| 035 | |a (DE-627)1584414928 | ||
| 035 | |a (DE-576)514414928 | ||
| 035 | |a (DE-599)BSZ514414928 | ||
| 035 | |a (OCoLC)1341024158 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Weller, Michael |d 1962- |e VerfasserIn |0 (DE-588)130838039 |0 (DE-627)506356701 |0 (DE-576)29836834X |4 aut | |
| 245 | 1 | 0 | |a Go, no-go decision making for phase 3 clinical trials |b ACT IV revisited - authors' reply |c Michael Weller, Nicholas Butowski, David D Tran, Lawrence D Recht, Michael Lim, Hal Hirte, Lynn Ashby, Laszlo Mechtler, Samuel A Goldlust, Fabio Iwamoto, Jan Drappatz, Donald M O'Rourke, Mark Wong, Mark G Hamilton, Gaetano Finocchiaro, James Perry, Wolfgang Wick, Jennifer Green, Yi He, Christopher D Turner, Michael J Yellin, Tibor Keler, Thomas A Davis, Roger Stupp, John H Sampson |
| 264 | 1 | |c 1 December 2017 | |
| 300 | |a 2 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 26.11.2018 | ||
| 700 | 1 | |a Wick, Wolfgang |d 1970- |e VerfasserIn |0 (DE-588)120297736 |0 (DE-627)080586929 |0 (DE-576)186221320 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The lancet. Oncology |d London : The Lancet Publ. Group, 2000 |g 18(2017), 12, Seite e709-e710 |h Online-Ressource |w (DE-627)325349770 |w (DE-600)2035574-9 |w (DE-576)100517544 |x 1474-5488 |7 nnas |a Go, no-go decision making for phase 3 clinical trials ACT IV revisited - authors' reply |
| 773 | 1 | 8 | |g volume:18 |g year:2017 |g number:12 |g pages:e709-e710 |g extent:2 |a Go, no-go decision making for phase 3 clinical trials ACT IV revisited - authors' reply |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S1470-2045(17)30856-2 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1470204517308562 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181126 | ||
| 993 | |a Editorial | ||
| 994 | |a 2017 | ||
| 998 | |g 120297736 |a Wick, Wolfgang |m 120297736:Wick, Wolfgang |d 910000 |d 911100 |e 910000PW120297736 |e 911100PW120297736 |k 0/910000/ |k 1/910000/911100/ |p 17 | ||
| 999 | |a KXP-PPN1584414928 |e 3034028466 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1584414928","id":{"doi":["10.1016/S1470-2045(17)30856-2"],"eki":["1584414928"]},"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"1 December 2017"}],"person":[{"given":"Michael","family":"Weller","role":"aut","display":"Weller, Michael"},{"display":"Wick, Wolfgang","family":"Wick","role":"aut","given":"Wolfgang"}],"language":["eng"],"relHost":[{"origin":[{"dateIssuedKey":"2000","publisherPlace":"London","dateIssuedDisp":"2000-","publisher":"The Lancet Publ. Group"}],"language":["eng"],"pubHistory":["0.2000 -"],"titleAlt":[{"title":"The lancet <London> / Oncology"}],"recId":"325349770","id":{"zdb":["2035574-9"],"eki":["325349770"],"issn":["1474-5488"]},"part":{"pages":"e709-e710","year":"2017","issue":"12","extent":"2","volume":"18","text":"18(2017), 12, Seite e709-e710"},"disp":"Go, no-go decision making for phase 3 clinical trials ACT IV revisited - authors' replyThe lancet. Oncology","type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 22.09.2021"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"lancet","partname":"Oncology","title":"The lancet"}]}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Michael Weller, Nicholas Butowski, David D Tran, Lawrence D Recht, Michael Lim, Hal Hirte, Lynn Ashby, Laszlo Mechtler, Samuel A Goldlust, Fabio Iwamoto, Jan Drappatz, Donald M O'Rourke, Mark Wong, Mark G Hamilton, Gaetano Finocchiaro, James Perry, Wolfgang Wick, Jennifer Green, Yi He, Christopher D Turner, Michael J Yellin, Tibor Keler, Thomas A Davis, Roger Stupp, John H Sampson"]},"physDesc":[{"extent":"2 S."}],"title":[{"title_sort":"Go, no-go decision making for phase 3 clinical trials","subtitle":"ACT IV revisited - authors' reply","title":"Go, no-go decision making for phase 3 clinical trials"}],"note":["Gesehen am 26.11.2018"]} | ||
| SRT | |a WELLERMICHGONOGODECI1201 | ||